The tropomyosin 3.1/3.2 inhibitor ATM-3507 alters B-cell actin dynamics and impairs the growth and motility of diffuse large B-cell lymphoma cell lines
Tpm3.1/3.2 orchestrates key actin-driven processes in B cells, and drugs that target Tpm3.1/3.2 may be useful adjuncts for treating DLBCL.
Authors
- Michael R. Gold (ORCID: https://orcid.org/0000-0003-1222-3191)
- Kate Choi (ORCID: https://orcid.org/0000-0002-7959-1944)
- Abhishek Bedi (ORCID: https://orcid.org/0000-0001-7852-7310)
- Alyssa Iskierski
Institutions
- University of British Columbia (CA)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-05
- DOI
- https://doi.org/10.3389/fimmu.2025.1668379
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Sciences and Engineering Research Council of Canada